PMID- 35379161
OWN - NLM
STAT- MEDLINE
DCOM- 20220830
LR  - 20230714
IS  - 2212-3989 (Electronic)
IS  - 1871-5265 (Linking)
VI  - 22
IP  - 6
DP  - 2022
TI  - The Effect of Curcumin on the Expression of INFgamma, TNF-alpha, and iNOS Genes in PBMCs 
      Infected with Leishmania major [MRHO/IR/75/ER].
PG  - e040422203031
LID - 10.2174/1871526522666220404083220 [doi]
AB  - BACKGROUND: Leishmaniasis, caused by the Leishmania parasite, is one of the most 
      important tropical neglected diseases. The urgent search for effective, 
      inexpensive, and preferably herbal anti-leishmanial agents, is needed. OBJECTIVE: 
      Curcumin is a natural polyphenolic compound derived from turmeric that is well 
      known for its antioxidant, anti-inflammatory, anti-tumor, and anti-cancer 
      activity. METHODS: The present work evaluates the anti-leishmanial [Leishmania 
      major] activity of curcumin. The infected PBMCs were treated with curcumin. The 
      ROS level at 6, 12, 24 h and gene expression levels at 24, 48, and 72 h of PBMCs 
      after treatment with curcumin were determined. RESULTS: Based on the results, the 
      curcumin concentrations of 268 muM [24 h] and 181.2 muM [72 h] were defined as IC50 
      against L. major promastigotes. Treatment of L. major infected-peripheral blood 
      mononuclear cells [PBMCs] with IC50 concentrations of curcumin, depending on 
      exposure time, significantly induced the reactive oxygen species [ROS] generation 
      and increased the expression levels of interferongamma [IFN-gamma], tumor necrosis 
      factor-alpha [TNF-alpha], and nitric oxide synthase [iNOS] genes. CONCLUSION: These 
      findings suggest the potential of curcumin against Leishmaniasis.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Alinejad, Soheila
AU  - Alinejad S
AD  - Cellular and Molecular Research Center, Cellular and Molecular Medicine Institute 
      & Department of Medical Parasitology and Mycology, Urmia University of Medical 
      Sciences, Urmia, Iran.
AD  - Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran.
FAU - Khademvatan, Shahram
AU  - Khademvatan S
AD  - Cellular and Molecular Research Center, Cellular and Molecular Medicine Institute 
      & Department of Medical Parasitology and Mycology, Urmia University of Medical 
      Sciences, Urmia, Iran.
FAU - Amani, Shahla
AU  - Amani S
AD  - Cellular and Molecular Research Center, Cellular and Molecular Medicine Institute 
      & Department of Medical Parasitology and Mycology, Urmia University of Medical 
      Sciences, Urmia, Iran.
AD  - Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran.
FAU - Asadi, Negar
AU  - Asadi N
AD  - Cellular and Molecular Research Center, Cellular and Molecular Medicine Institute 
      & Department of Medical Parasitology and Mycology, Urmia University of Medical 
      Sciences, Urmia, Iran.
AD  - Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran.
FAU - Tappeh, Khosrow Hazrati
AU  - Tappeh KH
AD  - Cellular and Molecular Research Center, Cellular and Molecular Medicine Institute 
      & Department of Medical Parasitology and Mycology, Urmia University of Medical 
      Sciences, Urmia, Iran.
FAU - Yousefi, Elham
AU  - Yousefi E
AD  - Cellular and Molecular Research Center, Cellular and Molecular Medicine Institute 
      & Department of Medical Parasitology and Mycology, Urmia University of Medical 
      Sciences, Urmia, Iran.
FAU - Miandoabi, Touraj
AU  - Miandoabi T
AD  - Cellular and Molecular Research Center, Cellular and Molecular Medicine Institute 
      & Department of Medical Parasitology and Mycology, Urmia University of Medical 
      Sciences, Urmia, Iran.
LA  - eng
GR  - 9298/Research Project of the Cellular and Molecular Research Center of Urmia 
      University of Medical Science/
PT  - Journal Article
PL  - United Arab Emirates
TA  - Infect Disord Drug Targets
JT  - Infectious disorders drug targets
JID - 101269158
RN  - 0 (IFNG protein, human)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 82115-62-6 (Interferon-gamma)
RN  - EC 1.14.13.39 (NOS2 protein, human)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - IT942ZTH98 (Curcumin)
SB  - IM
MH  - *Curcumin
MH  - Humans
MH  - Interferon-gamma
MH  - *Leishmania major
MH  - *Leishmaniasis
MH  - Leukocytes, Mononuclear
MH  - Nitric Oxide Synthase Type II
MH  - Reactive Oxygen Species
MH  - Tumor Necrosis Factor-alpha
OTO - NOTNLM
OT  - Curcumin
OT  - Leishmania major
OT  - PBMCs
OT  - gene expression
OT  - interferon gamma
OT  - tumor necrosis factor
EDAT- 2022/04/06 06:00
MHDA- 2022/08/31 06:00
CRDT- 2022/04/05 05:26
PHST- 2021/11/10 00:00 [received]
PHST- 2022/01/27 00:00 [revised]
PHST- 2022/02/15 00:00 [accepted]
PHST- 2022/04/06 06:00 [pubmed]
PHST- 2022/08/31 06:00 [medline]
PHST- 2022/04/05 05:26 [entrez]
AID - IDDT-EPUB-122206 [pii]
AID - 10.2174/1871526522666220404083220 [doi]
PST - ppublish
SO  - Infect Disord Drug Targets. 2022;22(6):e040422203031. doi: 
      10.2174/1871526522666220404083220.